PD-1/PD-L1抑制剂联合抗血管生成药物治疗晚期三阴性乳腺癌的研究进展  

Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors inTreatment of Advanced Triple-negative Breast Cancer

作　　者：黄世芬 令晓玲[2,3,4] HUANG Shifen;LING Xiaoling(First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Department of Oncology,The First Hospital of Lanzhou University,Lanzhou 730000,China;Gansu Province Key Laboratory of Biotherapy and Regenerative Medicine,Lanzhou 730000,China;Department of Oncology,Donggang Hospital,The First Hospital of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]兰州大学第一医院肿瘤内科,兰州730000 [3]甘肃省生物治疗与再生医学重点实验室,兰州730000 [4]兰州大学第一医院东岗院区肿瘤科,兰州730000

出　　处：《肿瘤防治研究》2021年第1期75-81,共7页Cancer Research on Prevention and Treatment

基　　金：甘肃省生物治疗与再生医学重点实验室资助项目(zdsyskfkt-201706)(临床研究注册号ChiCRTOIC-16008894);兰州市科技局资助项目(2019-ZD-42)。

摘　　要：晚期三阴性乳腺癌较其他亚型乳腺癌的治疗手段少、生存期短、预后差。近年飞速发展的免疫治疗有望延长晚期三阴性乳腺癌的生存时间,但是多项临床研究提示PD-1/PD-L1抑制剂单药治疗晚期三阴性乳腺癌有效率低。新近研究显示抗血管生成药物的治疗不仅可以使血管正常化,抑制肿瘤生长,还可以增强免疫治疗的疗效,与PD-1/PD-L1抑制剂联合治疗有协同增效的作用。本文通过分析PD-1/PD-L1抑制剂和抗血管生成药物的作用机制,回顾关于两药联用治疗晚期三阴性乳腺癌的临床前及临床研究,汇总其疗效及安全性,旨在为晚期三阴性乳腺癌的治疗策略提供新的角度和思路。Advanced triple-negative breast cancer(TNBC)has less treatments,shorter survival time and poorer prognosis than other subtypes of breast cancer.The rapid development of immunotherapy in recent years is expected to prolong the survival time of advanced TNBC patients,but multiple clinical studies have suggested that PD-1/PD-L1 inhibitor monotherapy have a low efficiency in the treatment of advanced TNBC.Recent studies have shown that the treatment with angiogenesis inhibitors can not only normalize blood vessels and inhibit tumor growth,but also enhance the efficacy of immunotherapy.Angiogenesis inhibitors combined with PD-1/PD-L1 inhibitors have synergistic effects.This article analyzes the mechanism of PD-1/PD-L1 inhibitors and angiogenesis inhibitors,reviews the preclinical and clinical studies on the combination of two types of drugs in the treatment of advanced TNBC and summarizes their efficacy and safety,to provide new perspectives and ideas for the treatment strategy of advanced TNBC.

关 键 词：晚期三阴性乳腺癌 PD-1/PD-L1抑制剂 抗血管生成药物 

分 类 号：R737.9[医药卫生—肿瘤]